0001127602-21-014110.txt : 20210420 0001127602-21-014110.hdr.sgml : 20210420 20210420160345 ACCESSION NUMBER: 0001127602-21-014110 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210416 FILED AS OF DATE: 20210420 DATE AS OF CHANGE: 20210420 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bancel Stephane CENTRAL INDEX KEY: 0001443340 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 21837859 MAIL ADDRESS: STREET 1: 320 BENT STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2021-04-16 0001682852 Moderna, Inc. MRNA 0001443340 Bancel Stephane C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 1 Chief Executive Officer Common Stock 2021-04-16 4 S 0 400 158.84 D 76938 I See Footnote Common Stock 2021-04-16 4 S 0 700 160.18 D 76238 I See Footnote Common Stock 2021-04-16 4 S 0 1530 161.59 D 74708 I See Footnote Common Stock 2021-04-16 4 S 0 600 162.38 D 74108 I See Footnote Common Stock 2021-04-16 4 S 0 500 163.50 D 73608 I See Footnote Common Stock 2021-04-16 4 S 0 100 164.48 D 73508 I See Footnote Common Stock 2021-04-16 4 S 0 1131 166.24 D 72377 I See Footnote Common Stock 2021-04-16 4 S 0 1100 167.18 D 71277 I See Footnote Common Stock 2021-04-16 4 S 0 500 168.42 D 70777 I See Footnote Common Stock 2021-04-16 4 S 0 1017 169.42 D 69760 I See Footnote Common Stock 2021-04-16 4 S 0 2938 170.42 D 66822 I See Footnote Common Stock 2021-04-16 4 S 0 530 171.42 D 66292 I See Footnote Common Stock 6356868 D Common Stock 7454880 I See Footnote Common Stock 9050372 I See Footnote This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.59 to $159.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.74 to $160.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.96 to $161.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.09 to $163.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.12 to $164.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.60 to $166.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $166.76 to $167.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $167.84 to $168.78. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $168.87 to $169.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $169.95 to $170.89. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $171.06 to $171.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. /s/ Brian Sandstrom, as Attorney-in-Fact 2021-04-20